Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, Chinese medical-device maker Mindray Medical (NYSE: MR) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Mindray's business and see what CAPS investors are saying about the stock right now.

Mindray facts

Headquarters (Founded) Shenzhen, China (1991)
Market Cap $3.2 billion
Industry Health care equipment
Trailing-12-Month Revenue $682.2 million
Management Chairman/Co-CEO Hang Xu (since 1991)
Founder/Co-CEO Xiting Li (since 1991)
Return on Equity (Average, Past 3 Years) 23.5%
Cash/Debt $381.9 million / $6.2 million
Dividend Yield 0.7%
Competitors Abbott Labs (NYSE: ABT)
General Electric (NYSE: GE)
Baxter International (NYSE: BAX)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 98% of the 1,518 members who have rated Mindray believe the stock will outperform the S&P 500 going forward. These bulls include iddqkfyou and All-Star mrindependent, who is ranked in the top 2% of our community.

Earlier this year, iddqkfyou highlighted Mindray as a healthy opportunity: "I am going to hold my breath and not buy into the stereotype that everything made in China is bad. As the median age continues to increase, Chinese are going to have to spend their savings on something, and it is as likely to be medical care as education."

Fools remaindrawn to Mindray's low-cost position in China's ever-growing diagnostic device space. Over the next five years, Mindray is even expected to grow profits at a faster rate (21.8% per annum) than gorilla rivals General Electric (13.3%), Abbott (10.2%), and Baxter (10.1%), as well as other medical-device giants such as Medtronic (NYSE: MDT) (9.2%) and Johnson & Johnson (NYSE: JNJ) (6.2%). More importantly, Mindray's current valuation, as All-Star mrindependent explains, offers an inexpensive way to go for that growth:

After adjusting the share price downward to reflect the company's net cash position of $3.70 per share, I calculate that Mindray Medical is selling for about 14 times its forward eps. Considering this company's impressive operations history and outstanding growth prospects as a Chinese maker of medical devices, this seems like a deal. The auditor is Price Waterhouse Coopers -- so not much chance of fraud.

What do you think about Mindray, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Mindray is a Motley Fool Rule Breakers recommendation. Johnson & Johnson is a choice of Income Investor. The Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days.

True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community. The Fool's disclosure policy always gets a perfect score.